Compare Merck & Co., Inc. (MRK) vs Northrop Grumman Corporation (NOC) Price & Performance

Merck & Co., Inc.Trade

Northrop Grumman CorporationTrade

Price performance (Past 24H)

Key statistics

Merck & Co., Inc. vs Northrop Grumman Corporation — how do they compare? Merck & Co., Inc. trades at $125.97 (market cap $307.25B), while Northrop Grumman Corporation trades at $512 (market cap $74.42B). The key difference: Merck & Co., Inc. is far larger — about 4.1× Northrop Grumman Corporation's market cap, and Merck & Co., Inc. pays the higher dividend (2.73%). Which is the better fit depends on your goals.

	MRK	NOC
Market Cap	$307.25B	$74.42B
Sector	Health	Industrials
52-Week High	$129.52	$768.02
52-Week Low	$77.60	$496.02
Enterprise Value	$350.66B	$88.65B
Dividend Yield	2.73%	1.79%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Merck & Co., Inc.

Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.

Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.

Northrop Grumman Corporation

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

MRK

Over 180 companies develop 200+ PD-1/PD-L1 inhibitors, reshaping cancer treatment landscape.Delveinsight · 6 hours agoBullish Schwab U.S. Dividend Equity ETF (SCHD) remains a Buy for strong dividends and growth potential.Seeking Alpha · 2 days agoBullish Merck rated Strong Buy on oncology growth and new LIPFENDRA launch for cholesterol controlSeeking Alpha · 4 days agoBullish View details →

NOC

Northrop Grumman CEO hints space robots could be weaponized, leaving decision to US government.Forbes · 8 hours agoBullish Northrop Grumman reports Q2 2026 financial results and hosts earnings call webcastGlobeNewsWire · 16 hours agoNeutral Northrop Grumman expects 4.1% revenue growth but a 3.8% EPS decline in upcoming earnings report.Stuart Mooney · 1 day agoNeutral View details →

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

About Northrop Grumman Corporation

Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.